SMARCB1 and sarcoma: As an illustration of the importance of this complex in soft tissue sarcomas, we have recently shown that the first-in-class, first-in-human highly specific inhibitor tazemetostat (an EZH2 inhibitor) is associated with an excellent safety profile and promising anti-tumor activity in SMARCB1-deleted sarcomas [21].